BioCentury
ARTICLE | Clinical News

Zolinza vorinostat regulatory update

December 3, 2007 8:00 AM UTC

MRK submitted an MAA to EMEA for vorinostat to treat advanced refractory cutaneous T cell lymphoma (CTCL). MRK markets the HDAC inhibitor in the U.S. as Zolinza. MRK acquired the drug, which has Orph...